2 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMOCompleted
To evaluatie the long term safety of treatment with osilodrostat for patients with Cushing Syndrome. In addition to evaluating the proportion of patients with clinical benefit (as assessed by the investigator) and determening frequency, severity and…